Mapp's Ebola treatment comes through in a preclinical study

Ebola virus under an electron microscope--Courtesy of CDC

Tiny Mapp Biopharmaceutical's much-scrutinized Ebola treatment proved 100% effective in animal studies, the company said, stoking hopes that the investigational therapy can help curb an outbreak of the virus. In a primate trial, ZMapp rescued all 18 rhesus macaques infected with Ebola after 5 days, according to results published in Nature. The treatment, a combination of three monoclonal antibodies, has been administered to 7 people infected with the virus since the latest outbreak began despite never having completed human trials. More